Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desipramine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Norpramin Tablets, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg, of Validus Pharmaceuticals. Desipramine Hydrochloride Tablets, USP are indicated for the treatment of depression.
Desipramine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg have an estimated market size of $7 million for twelve months ending March 2021 according to IQVIA.
Alembic has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…